Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 31 to 40 of 480 total matches.

Ertugliflozin for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Apr 23, 2018  (Issue 1545)
as monotherapy or in addition to other drugs, they reduce A1C by 0.5-1%. SGLT2 inhibitors also reduce systolic ...
The FDA has approved the sodium-glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin (Merck) for treatment of adults with type 2 diabetes, both alone (Steglatro) and in fixed-dose combinations with metformin (Segluromet) and sitagliptin (Steglujan). Ertugliflozin is the fourth SGLT2 inhibitor to be approved in the US. All four are available in combination with metformin and three are available in combination with a dipeptidyl peptidase-4 (DPP-4) inhibitor (see Table 3).
Med Lett Drugs Ther. 2018 Apr 23;60(1545):70-2 | Show Introduction Hide Introduction

In Brief: Avelumab (Bavencio) for Metastatic Merkel Cell Carcinoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 17, 2017  (Issue 1525)
-human programmed death ligand 1 (PD-L1) blocking antibody avelumab (Bavencio – EMD Serono/Pfizer) for treatment ...
The FDA has approved the fully-human programmed death ligand 1 (PD-L1) blocking antibody avelumab (Bavencio – EMD Serono/Pfizer) for treatment of metastatic Merkel cell carcinoma (MCC) in patients ≥12 years old. Avelumab is the first drug to be approved in the US for this rare skin cancer. About 1600 people in the US, most commonly older adults (mean age at presentation is 75 years), are diagnosed each year with MCC. Most of these patients can be treated with surgical resection, but ~50% will have a recurrence and >30% will eventually have metastatic disease. Median progression-free...
Med Lett Drugs Ther. 2017 Jul 17;59(1525):e120 | Show Introduction Hide Introduction

Addendum: Brolucizumab (Beovu) for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • Mar 09, 2020  (Issue 1593)
10 issue.1 On February 23, the American Society of Retina Specialists reported that 14 patients who ...
We reviewed brolucizumab (Beovu – Novartis) for treatment of neovascular (wet) age-related macular degeneration in our February 10 issue. On February 23, the American Society of Retina Specialists reported that 14 patients who received the drug have developed retinal vasculitis, a potentially vision-threatening complication.
Med Lett Drugs Ther. 2020 Mar 9;62(1593):40 | Show Introduction Hide Introduction

In Brief: Semglee - Insulin Glargine Interchangeable with Lantus

   
The Medical Letter on Drugs and Therapeutics • Oct 04, 2021  (Issue 1634)
will be the same if the patient switches between the reference product and the biosimilar.1 In an open ...
Insulin glargine-yfgn (Semglee – Viatris), a follow-on insulin glargine product, has now received interchangeability status with the reference product Lantus from the FDA. It is the first biosimilar insulin product to receive this designation in the US. Now a pharmacist can substitute Semglee for Lantus as a lower-cost alternative without permission from the prescriber.
Med Lett Drugs Ther. 2021 Oct 4;63(1634):159-60 | Show Introduction Hide Introduction

Bremelanotide (Vyleesi) for Hypoactive Sexual Desire Disorder

   
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019  (Issue 1577)
; flibanserin (Addyi), which was approved in 2015, was the first.1 Pronunciation Key Bremelanotide: bre” me ...
The FDA has approved bremelanotide (Vyleesi – Amag), a melanocortin receptor agonist, for subcutaneous treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Bremelanotide is not approved for use in men or postmenopausal women. It is the second drug to be approved in the US for this indication; flibanserin (Addyi), which was approved in 2015, was the first.
Med Lett Drugs Ther. 2019 Jul 29;61(1577):114-6 | Show Introduction Hide Introduction

In Brief: Oritavancin (Kimyrsa) for Skin and Skin Structure Infections (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021  (Issue 1631)
indication.1 Kimyrsa has a smaller infusion volume (250 mL vs 1 L) and a shorter infusion time (1 hour vs 3 ...
The FDA has approved Kimyrsa (Melinta), a new IV formulation of the long-acting lipoglycopeptide antibiotic oritavancin, for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. Orbactiv (Melinta), another IV formulation of oritavancin, was approved in 2014 for the same indication. Kimyrsa has a smaller infusion volume (250 mL vs 1 L) and a shorter infusion time (1 hour vs 3 hours) compared to Orbactiv (see Table 1).
Med Lett Drugs Ther. 2021 Aug 23;63(1631):e1-2 | Show Introduction Hide Introduction

Paxlovid for Treatment of COVID-19

   
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022  (Issue 1642)
Authorization (EUA) for the investigational antiviral drug nirmatrelvir copackaged with the HIV-1 protease ...
On December 22, 2021, the FDA issued an Emergency Use Authorization (EUA) for the investigational antiviral drug nirmatrelvir copackaged with the HIV-1 protease inhibitor ritonavir (Paxlovid – Pfizer) for oral treatment of mild to moderate COVID-19 in outpatients ≥12 years old who weigh at least 40 kg and are at high risk of progressing to severe disease, including hospitalization or death. Paxlovid was the first oral antiviral drug to be authorized in the US for treatment of COVID-19; Merck's oral antiviral drug molnupiravir was granted an EUA for treatment of COVID-19 on December 23,...
Med Lett Drugs Ther. 2022 Jan 24;64(1642):9-10 | Show Introduction Hide Introduction

Emicizumab (Hemlibra) for Subcutaneous Prophylaxis in Hemophilia A

   
The Medical Letter on Drugs and Therapeutics • May 20, 2019  (Issue 1572)
-linked recessive deficiency of coagulation factor VIII that occurs in about 1 in 5000 male births, hemophilia ...
The FDA has approved emicizumab-kxwh (Hemlibra – Genentech), a subcutaneously injected, factor IXa- and X-directed antibody, for routine prophylaxis to prevent or reduce bleeding episodes in patients with hemophilia A. Emicizumab is not recommended for treatment of bleeding.
Med Lett Drugs Ther. 2019 May 20;61(1572):77-9 | Show Introduction Hide Introduction

Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection

   
The Medical Letter on Drugs and Therapeutics • Oct 09, 2017  (Issue 1531)
-experienced patients. Mavyret is also approved for treatmentnaive patients. HCV GENOTYPES — HCV genotype 1 accounts ...
The FDA has approved Mavyret (Abbvie) and Vosevi (Gilead), two new fixed-dose combinations of direct-acting antiviral (DAA) drugs, for treatment of chronic hepatitis C virus (HCV) infection caused by any of the six major HCV genotypes in patients without cirrhosis or with compensated cirrhosis. Both are approved for use in treatment-experienced patients. Mavyret is also approved for treatment-naive patients.
Med Lett Drugs Ther. 2017 Oct 9;59(1531):166-70 | Show Introduction Hide Introduction

Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 19, 2021  (Issue 1622)
(Johnson & Johnson) 5 mg/120 mg ER tabs OTC 1 tab bid ≥12 yrs: 1 tab bid Pseudoephedrine can cause ...
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Med Lett Drugs Ther. 2021 Apr 19;63(1622):e63-65 | Show Introduction Hide Introduction